← Leaderboards
Robert Alan Baiocchi
Ohio State University
$3,789,234
Attributed
$5,731,486
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $749.9K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,981,295 · 8
By mechanism
R01$2,290,108 · 1
P01$1,357,004 · 1
RC2$999,864 · 1
R38$422,504 · 1
R21$408,523 · 1
P30$249,809 · 1
Top collaborators
- John C Byrd5 shared
- Rosa Lapalombella5 shared
- Chenglong Li2 shared
- Ginny L Bumgardner1 shared
- Zihai Li1 shared
- Raphael E. Pollock1 shared
Most similar at Ohio State University
Same institution · by research overlap
- Raphael E. Pollock$16,802,076
- Michael A Caligiuri$65,062,344
- Peter G. Shields$24,078,159
- Mary Ellen Wewers$16,751,966
- Heather D Hampel$2,802,697
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsTumorPre-ClinicalClinical TrialsIn VivoImmuneLymphomaPathway InteractionsPharmaceutical PreparationsNovel StrategiesMalignant NeoplasmsCombined Modality TherapyEpigenetic ProcessTranslationsInnovationOverexpressionGene ExpressionPreventRegulationLeadAnimal ModelChromatinTherapeutic TargetTumor Suppressor Genes
Grant awards (18)
The Ohio State University Research in Residency Physician Scientist Initiative$422,504
R38 · FY2025 · AI
Targeting the Tumor Microenvironment in Patients with AIDS-Associated EBV+ Diffuse Large B Cell Lymphoma$249,809
P30 · FY2024 · CA
Project 3: Targeting PRMT5 in Mantle Cell Lymphoma$265,220
P01 · FY2022 · CA · contact PI
Targeted Therapies for Richters Transformation$463,172
R01 · FY2021 · CA
Project 3: Targeting PRMT5 in Mantle Cell Lymphoma$270,632
P01 · FY2021 · CA · contact PI
Targeted Therapies for Richters Transformation$463,172
R01 · FY2020 · CA
Project 3: Targeting PRMT5 in Mantle Cell Lymphoma$270,632
P01 · FY2020 · CA · contact PI
Targeted Therapies for Richters Transformation$449,278
R01 · FY2019 · CA
Project 3: Targeting PRMT5 in Mantle Cell Lymphoma$262,513
P01 · FY2019 · CA · contact PI
Targeted Therapies for Richters Transformation$461,935
R01 · FY2018 · CA
Project 3: Targeting PRMT5 in Mantle Cell Lymphoma$288,007
P01 · FY2018 · CA · contact PI
Targeted Therapies for Richters Transformation$452,551
R01 · FY2017 · CA
Development of novel compounds to inhibit PRMT5 enzyme in high grade astrocytomas$221,022
R21 · FY2011 · NS · contact PI
Development of Vaccine Strategies to prevent EBV+ Lymphoma in Patients with HIV$499,864
RC2 · FY2010 · CA · contact PI
Development of novel compounds to inhibit PRMT5 enzyme in high grade astrocytomas$187,501
R21 · FY2010 · NS · contact PI
Development of Vaccine Strategies to prevent EBV+ Lymphoma in Patients with HIV$500,000
RC2 · FY2009 · CA · contact PI
PTLD: cytokine production and gene polymorphisms$74,750
R03 · FY2005 · CA
BIOLOGIC MODIFIER THERAPIES IN AIDS MALIGNANCIES$178,733
U01 · FY2003 · CA